))
Lymphoma highlights at EHA 2023: sequencing bispecifics & CAR-T cells, bridging therapy & toxicity management
Manage episode 366255739 series 2838329
内容由VJHemOnc提供。所有播客内容（包括剧集、图形和播客描述）均由 VJHemOnc 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品，您可以按照此处概述的流程进行操作https://zh.player.fm/legal。
The treatment landscape of large B-cell lymphoma (LBCL) has transformed in recent years, with novel immunotherapies including bispecific antibodies and CAR-T cells demonstrating promising results. At the 2023 EHA meeting, leading experts from around the globe came together to discuss the latest updates in all areas of hematological oncology.
In this podcast, you will hear from Gloria Iacoboni, MD, Vall d’Hebron University Hospital, Barcelona, Spain, and Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, who share some insights into recent advances in CAR-T therapy and bispecific antibodies in the treatment of LBCL. Topics covered include the sequencing of these agents, bridging therapies, and managing toxicities and cytopenias after CAR-T therapy.
200集单集
分享
